This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2007 Jul 7;370(9581):24; author reply 24-5.

doi: 10.1016/S0140-6736(07)61035-6.

Renin-angiotensin system and cardiovascular risk

Luca Mascitelli, Francesca Pezzetta

PMID: 17617259
DOI: 10.1016/S0140-6736(07)61035-6

Comment

Renin-angiotensin system and cardiovascular risk

Luca Mascitelli et al. Lancet. 2007.

. 2007 Jul 7;370(9581):24; author reply 24-5.

doi: 10.1016/S0140-6736(07)61035-6.

Authors

Luca Mascitelli, Francesca Pezzetta

PMID: 17617259
DOI: 10.1016/S0140-6736(07)61035-6

No abstract available

PubMed Disclaimer

Comment on

Renin-angiotensin system and cardiovascular risk.
Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Schmieder RE, et al. Lancet. 2007 Apr 7;369(9568):1208-19. doi: 10.1016/S0140-6736(07)60242-6. Lancet. 2007. PMID: 17416265 Review.

Similar articles

Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany.
Adarkwah CC, Gandjour A. Adarkwah CC, et al. Int J Technol Assess Health Care. 2010 Jan;26(1):62-70. doi: 10.1017/S0266462309990584. Int J Technol Assess Health Care. 2010. PMID: 20059782
A cost-effectiveness analysis of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in diabetic nephropathy.
Stafylas PC, Sarafidis PA, Grekas DM, Lasaridis AN. Stafylas PC, et al. J Clin Hypertens (Greenwich). 2007 Oct;9(10):751-9. doi: 10.1111/j.1524-6175.2007.07182.x. J Clin Hypertens (Greenwich). 2007. PMID: 17917502 Free PMC article.
[Is increased use of angiotensin II antagonists worth its money?].
Madsen HK. Madsen HK. Ugeskr Laeger. 2005 Jan 10;167(2):190-1. Ugeskr Laeger. 2005. PMID: 15697138 Danish. No abstract available.
Renoprotection by blocking the RAAS in diabetic nephropathy--fact or fiction?
Rossing P, Parving HH, de Zeeuw D. Rossing P, et al. Nephrol Dial Transplant. 2006 Sep;21(9):2354-7; discussion 2357-8. doi: 10.1093/ndt/gfl454. Nephrol Dial Transplant. 2006. PMID: 16928724 Review. No abstract available.
[Debate concerning the optimal blockage of the renin-angiotensin system].
Choukroun G. Choukroun G. Nephrol Ther. 2010 Jan;6 Spec No 1:H1-9. doi: 10.1016/S1769-7255(10)70001-8. Nephrol Ther. 2010. PMID: 20129454 Review. French. No abstract available.

See all similar articles

Cited by

Renin-angiotensin-aldosterone system blockade is associated with higher risk of contrast-induced acute kidney injury in patients with diabetes.
Ma M, Wan X, Gao M, Pan B, Chen D, Sun Q, Zhang M, Zhou C, Li T, Pan H, Shao W, Liu Z, Chen Y, Cao C. Ma M, et al. Aging (Albany NY). 2020 Apr 2;12(7):5858-5877. doi: 10.18632/aging.102982. Epub 2020 Apr 2. Aging (Albany NY). 2020. PMID: 32241961 Free PMC article.
NPA7: A Dual Receptor Activating Peptide That Inhibits Cardiac Oxidative Stress.
Ma X, Malsawmzuali JC, Moroni DG, Ma X, Zheng Y, Pan S, Wang Y, Sangaralingham SJ, Burnett JC Jr. Ma X, et al. Hypertension. 2025 Mar;82(3):463-475. doi: 10.1161/HYPERTENSIONAHA.124.23579. Epub 2025 Jan 8. Hypertension. 2025. PMID: 39772591

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information